Literature DB >> 26003532

Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.

Leandro H Gallo1, Katelyn N Nelson2, April N Meyer3, Daniel J Donoghue4.   

Abstract

The four receptor tyrosine kinases (RTKs) within the family of Fibroblast Growth Factor Receptors (FGFRs) are critical for normal development but also play an enormous role in oncogenesis. Mutations and/or abnormal expression often lead to constitutive dimerization and kinase activation of FGFRs, and represent the primary mechanism for aberrant signaling. Sequencing of human tumors has revealed a plethora of somatic mutations in FGFRs that are frequently identical to germline mutations in developmental syndromes, and has also identified novel FGFR fusion proteins arising from chromosomal rearrangements that contribute to malignancy. This review details approximately 200 specific point mutations in FGFRs and 40 different fusion proteins created by translocations involving FGFRs that have been identified in human cancer. This review discusses the effects of these genetic alterations on downstream signaling cascades, and the challenge of drug resistance in cancer treatment with antagonists of FGFRs.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Development; Fibroblast Growth Factor Receptor; Myeloproliferative syndrome; Rhabdomyosarcoma; Translocation

Mesh:

Substances:

Year:  2015        PMID: 26003532     DOI: 10.1016/j.cytogfr.2015.03.003

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  49 in total

Review 1.  The Structural and Functional Diversity of Intrinsically Disordered Regions in Transmembrane Proteins.

Authors:  Rajeswari Appadurai; Vladimir N Uversky; Anand Srivastava
Journal:  J Membr Biol       Date:  2019-05-28       Impact factor: 1.843

2.  Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.

Authors:  Hui Liu; Charles J Murphy; Florian A Karreth; Kristina B Emdal; Forest M White; Olivier Elemento; Alex Toker; Gerburg M Wulf; Lewis C Cantley
Journal:  Cancer Discov       Date:  2017-12-04       Impact factor: 39.397

3.  TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.

Authors:  Lipika Goyal; Lei Shi; Leah Y Liu; Ferran Fece de la Cruz; Jochen K Lennerz; Srivatsan Raghavan; Ignaty Leschiner; Liudmila Elagina; Giulia Siravegna; Raymond W S Ng; Phuong Vu; Krushna C Patra; Supriya K Saha; Raul N Uppot; Ron Arellano; Stephanie Reyes; Takeshi Sagara; Sachie Otsuki; Brandon Nadres; Heather A Shahzade; Ipsita Dey-Guha; Isobel J Fetter; Islam Baiev; Emily E Van Seventer; Janet E Murphy; Cristina R Ferrone; Kenneth K Tanabe; Vikram Deshpande; James J Harding; Rona Yaeger; Robin K Kelley; Alberto Bardelli; A John Iafrate; William C Hahn; Cyril H Benes; David T Ting; Hiroshi Hirai; Gad Getz; Dejan Juric; Andrew X Zhu; Ryan B Corcoran; Nabeel Bardeesy
Journal:  Cancer Discov       Date:  2019-05-20       Impact factor: 39.397

4.  Prolonged Partial Response to Bevacizumab and Valproic Acid in a Patient With Glioblastoma.

Authors:  Elena Fountzilas; Gary Palmer; David Vining; Apostolia-Maria Tsimberidou
Journal:  JCO Precis Oncol       Date:  2018-12-21

5.  Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

Authors:  K Martin Kortüm; Elias K Mai; Nur H Hanafiah; Chang-Xi Shi; Yuan-Xiao Zhu; Laura Bruins; Santiago Barrio; Patrick Jedlowski; Maximilian Merz; Jing Xu; Robert A Stewart; Mindaugas Andrulis; Anna Jauch; Jens Hillengass; Hartmut Goldschmidt; P Leif Bergsagel; Esteban Braggio; A Keith Stewart; Marc S Raab
Journal:  Blood       Date:  2016-07-25       Impact factor: 22.113

6.  Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas.

Authors:  Elizabeth Lenkiewicz; Smriti Malasi; Tara L Hogenson; Luis F Flores; Whitney Barham; William J Phillips; Alexander S Roesler; Kendall R Chambers; Nirakar Rajbhandari; Akimasa Hayashi; Corina E Antal; Michael Downes; Paul M Grandgenett; Michael A Hollingsworth; Derek Cridebring; Yuning Xiong; Jeong-Heon Lee; Zhenqing Ye; Huihuang Yan; Matthew C Hernandez; Jennifer L Leiting; Ronald M Evans; Tamas Ordog; Mark J Truty; Mitesh J Borad; Tannishtha Reya; Daniel D Von Hoff; Martin E Fernandez-Zapico; Michael T Barrett
Journal:  Cancer Res       Date:  2020-09-14       Impact factor: 12.701

7.  Kinase Activity of Fibroblast Growth Factor Receptor 3 Regulates Activity of the Papillomavirus E2 Protein.

Authors:  Fang Xie; Marsha DeSmet; Sriramana Kanginakudru; Leny Jose; Sara P Culleton; Timra Gilson; Chengxin Li; Elliot J Androphy
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

8.  FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.

Authors:  James M Cleary; Srivatsan Raghavan; Qibiao Wu; Yvonne Y Li; Liam F Spurr; Hersh V Gupta; Douglas A Rubinson; Isobel J Fetter; Jason L Hornick; Jonathan A Nowak; Giulia Siravegna; Lipika Goyal; Lei Shi; Lauren K Brais; Maureen Loftus; Atul B Shinagare; Thomas A Abrams; Thomas E Clancy; Jiping Wang; Anuj K Patel; Franck Brichory; Anne Vaslin Chessex; Ryan J Sullivan; Rachel B Keller; Sarah Denning; Emma R Hill; Geoffrey I Shapiro; Anna Pokorska-Bocci; Claudio Zanna; Kimmie Ng; Deborah Schrag; Pasi A Jänne; William C Hahn; Andrew D Cherniack; Ryan B Corcoran; Matthew Meyerson; Antoine Daina; Vincent Zoete; Nabeel Bardeesy; Brian M Wolpin
Journal:  Cancer Discov       Date:  2021-04-29       Impact factor: 39.397

Review 9.  Fusion-associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance.

Authors:  Suet Kee Loo; Megan E Yates; Sichun Yang; Steffi Oesterreich; Adrian V Lee; Xiao-Song Wang
Journal:  Genes Chromosomes Cancer       Date:  2022-02-17       Impact factor: 5.006

Review 10.  Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.

Authors:  Laura Pacini; Andrew D Jenks; Nadia Carvalho Lima; Paul H Huang
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.